Calliditas Therapeutics
Martin Allerbrand has diverse work experience in finance and business control. Martin recently joined Calliditas Therapeutics as Head of Business Control. Prior to that, they worked at Valneva as a Senior Business Controller for the Swedish site. Martin also had a brief role as a Senior Group FP&A at Loopia Group. Martin has experience as a Senior Group Business Controller/Project Lead at NCC AB. Martin has previously worked at Orkla Confectionery & Snacks Sverige, SCANIA FINANS AB, Shire Pharmaceuticals, AstraZeneca AB, and ManpowerGroup in various finance and business control positions.
Martin Allerbrand began their education in 1997 at Montgomery College, where they studied Macro Economics and English. Martin attended the college for one year before moving on to Stockholm University in 1998. At Stockholm University, Martin pursued a M.Sc. in Business and Administration, completing their studies in 2003. No specific degree was mentioned for either educational institution.
This person is not in any teams
Calliditas Therapeutics
2 followers
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.